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Abstract
Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with
bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary minerali-
zation of the calciﬁed matrix remains unclear. We examined the eﬀects of bisphosphonates on both the trabecular architecture and
matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one
receiving risedronate and the other alendronate at 5–6 times the clinical dose for osteoporosis treatment. After one year, the dogs
were killed, and samples from the ﬁrst lumbar vertebrae were examined using a combination of micro-computed tomography, ﬁnite
element modeling, and mechanical testing. By combining these methods, we examined the treatment eﬀects on the calciﬁed matrix
and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second
and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent
Young’s modulus, decreased bone turnover, increased calciﬁed matrix density, and increased microdamage. We could not detect any
change in the eﬀective Young’s modulus of the calciﬁed matrix in the bisphosphonate treated groups. The observed increase in
apparent Young’s modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calciﬁed
matrix modulus. We hypothesize that the expected increase in the Young’s modulus of the calciﬁed matrix due to the increased
calciﬁed matrix density was counteracted by the accumulation of microdamage.
 2003 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved.
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Introduction
Bisphosphonates, speciﬁc inhibitors of bone resorp-
tion, are gaining importance in the treatment of osteo-
porosis [7,36]. Bisphosphonates inhibit osteoclast
activity on the bone surface by causing early osteoclast
death, thus reducing the remodelling space, i.e., the
amount of bone undergoing active remodelling at any
speciﬁc time [33,35]. Bone mineral density (BMD) as
measured by dual energy X-ray absorptometry is in-
creased by increasing either the total volume of bone
(bone mass) or the mineralization of the calciﬁed bone
matrix [10,27,43]. It has been demonstrated that the
activation frequency (a histological measure of new re-
sorption sites) is reduced during bisphosphonate therapy
[6,28], temporarily disrupting the normal equilibrium
between bone resorption and formation. Although the
number of new resorption sites is reduced early in the
therapy program, the existing formation sites continue
to produce new bone matrix. The resultant phenome-
non, known as the bone remodelling transient, is associ-
ated with a rapid gain in bone mass early in the
treatment period. This transient behavior continues
until the active remodelling sites are ﬁlled in by osteo-
blast activity, reducing the remodelling space until a new
equilibrium is reached. The amount of bone aﬀected by
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the remodelling transient is determined by the change in
the number and size of active remodelling units and the
duration of the resorption and formation phases [15,31].
In addition to its eﬀect on the remodelling space, the
reduction in activation frequency also results in a slower
equilibrium remodelling rate. Because bone turnover is
reduced, the average age of the bone packets within the
calciﬁed matrix is increased. This results in increased
matrix mineralization [27,34]. The therapeutic eﬀect of
the bisphosphonate alendronate is thought to be due
primarily to an increase in mineralization [3,27]. While
increased mineralization should result in stiﬀer bone
material [8], concern exists that this frozen bone’ might
become brittle and/or accumulate microdamage [16,24].
Microdamage accumulation is normally prevented by
remodelling, and resorption spaces can be initiated by
microdamage [4,29,42]. Accumulated microdamage can
contribute to a reduction of bone Young’s modulus,
strength, and toughness and could possibly increase
fracture risk [5,44].
Recently, it has become possible to quantify the eﬀect
of changes in architecture and bone mass on the ap-
parent mechanical behavior of bone independent of the
mechanical properties of the calciﬁed matrix. Micro-
computed tomography (microCT) scanning and auto-
mated ﬁnite element (FE) methods [41] can be combined
to create a powerful method for the study of treatment-
induced changes in bone architecture at the trabecular
level (10–20 lm). Further, changes in the Young’s
modulus of the calciﬁed matrix (hereafter referred to as
the matrix modulus) can be investigated by combining
these methods with conventional mechanical testing
[9,22]. Thus, the contributions of both matrix properties
and trabecular architecture to the overall apparent mod-
ulus can be evaluated.
In this study we examined the eﬀect of long-term
treatment with high doses of two bisphosphonates,
alendronate and risedronate, in a canine model. We
investigated the changes induced by bisphosphonate
treament to both bone architecture and matrix modulus
as well as their contributions to the apparent Young’s
modulus. To interpret our ﬁndings, we examined
the eﬀect of bisphosphonates on remodelling, matrix
mineralization, and microdamage accumulation. Speciﬁ-
cally, we tested the hypothesis that high dose bis-
phosphonate treatment leads to increased secondary
mineralization and consequently an increase in the ma-
trix modulus.
Methods
Experimental design
The experimental design used in this study has been reported pre-
viously and will be brieﬂy summarized [24]. Thirty-six female beagle
dogs aged 1–2 years (control: 1.2± 0.4, risedronate: 1.1± 0.2, alendr-
onate: 1.2± 0.2 (y.o. ± SD)) were divided into 3 weight matched
groups. Dogs in the two treatment groups were treated daily with
risedronate (Procter and Gamble Pharmaceuticals Inc., Cincinnati,
OH) orally at a dose of 0.5 mg/kg/day or alendronate (Merck and Co.,
Inc., West Point, PA) orally at 1.0 mg/kg/day. Long-term treatment
was simulated using doses that were 5–6 times higher than the clinical
dose for osteoporosis. All dogs were treated for 12 months, then killed,
and the ﬁrst, second, and third lumbar vertebrae were removed. All
procedures were in accordance with approved NIH guidelines, under a
protocol approved by the Indiana University School of Medicine
Animal Care and Use Committee (Study #MD 1783).
Specimen preparation: microCT and mechanical testing
One cubic trabecular bone specimen with dimensions 5 · 5· 5 mm
was produced from the center of each ﬁrst lumbar (L1) vertebral body,
aligned with the anatomical axes in the cranial–caudal (CC), antero-
posterior (AP), and medial–lateral (ML) planes. Low speed, water
cooled diamond saws (EXAKT Apparatenbau, Norderstedt, Ger-
many; Ernst Leitz Wetzlar GmbH, Wetzlar, Germany) were used for
all sample preparation. Samples were stored in sealed plastic tubes at
)20 C, and care was taken to keep specimens moist during scanning
and testing.
A high-resolution microCT system (l-CT 20, Scanco Medical AG.,
Z€urich, Switzerland) was used to scan the specimens, resulting in re-
constructions with 18 · 18 · 18 lm cubic voxels. The microCT images
were segmented using thresholds chosen such that the volume of the
dataset matched that determined physically using Archimedes’ prin-
ciple [12]. Archimedes’ principle was also used to determine the bone
volume fraction (BV/TV) and the density of the calciﬁed matrix.
After scanning, each cubic specimen was tested in compression in
an 858 Bionix MTS hydraulic material testing machine (MTS Systems
Corporation, Minneapolis, MN). Specimens were tested non-destruc-
tively in compression to 6000 lstrain (apparent strain) at a strain rate
of 2000 lstrain/s in the AP and ML directions to determine the ap-
parent Young’s modulus. The apparent Young’s modulus of each
sample was calculated as the tangent of the linear portion of the stress–
strain curve at 5000 lstrain for the non-destructive tests (AP and ML
directions). The specimens were then tested to failure in the CC di-
rection with the same strain rate. The apparent Young’s modulus in
this direction was deﬁned as the slope of the steepest portion of the
stress–strain curve. Yield stress was deﬁned as the intercept between
the stress–strain curve and the line used to deﬁne the Young’s modulus
oﬀset by 0.2% strain. Ultimate stress was deﬁned as the peak stress
encountered during testing. All testing was performed on polished
platens lubricated with a low viscosity mineral oil to reduce the eﬀect
of friction [23].
Finite element models
The matrix modulus was calculated for all three directions using a
combination of ﬁnite element modeling and mechanical testing. This
combination was used because it enables the total apparent modulus to
be partitioned into contributions due to the matrix modulus and tra-
becular architecture [41]. All voxel microCT data were coarsened to 36
lm, then converted to a ﬁnite element mesh of 8 node cubic elements.
Coarsening was performed using a bone volume-preserving algorithm
[39]. The resulting meshes typically consisted of 400,000–700,000 ele-
ments. All elements were assigned an arbitrary matrix modulus of 1
GPa and a Poisson ratio of 0.3. Boundary values were assigned to
simulate an unconstrained compression test with no friction at the
platens. Because we used a matrix modulus of unity with a linear ﬁnite
element analysis, the apparent modulus obtained from the ﬁnite ele-
ment model can simply be scaled to match the apparent modulus from
each of the mechanical tests. The resulting scaling factor can be con-
sidered the matrix modulus of the sample [41]. This modulus represents
the average stiﬀness of the voxels of the bone matrix under the as-
sumption of homogeneous isotropic tissue properties (Fig. 1).
Simulation of increased mineralization
Bisphosphonate treatment has been previously observed to result in
both increased mineralization and a loss of the normal mineralization
gradient between superﬁcial and interstitial bone [3,31,34]. We used 4
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FE meshes from the residronate treated group to predict the eﬀects of
altered mineralization on the apparent modulus. Two conditions were
simulated: homogeneous mineralization representing bisphosphonate
treated bone and a heterogenous mineralization that was more repre-
sentative of normal bone with lower mineralization at the surface and
higher mineralization of the interstitial bone [40]. To accomplish the
simulations, an image erosion algorithm was used to identify bone
voxels within 36 lm of the surface. A 5% increase in total minerali-
zation was assumed for the bisphosphonate treated samples [3,28,34].
By assuming that bisphosphonate treatment mostly aﬀected surface
voxels, a lower relative mineralization was calculated for the normal
surface voxels. We then used either a linear or cubic relation as the
extreme boundaries for the relation between mineral content and
Young’s modulus [8]. After solving the FE models we compared the
apparent modulus in the CC direction for the normal (inhomogeneous
properties) and the treated (homogeneous properties) models.
Histomorphometry and microdamage
Dynamic histomorphometry and microdamage data from the sec-
ond and third lumbar vertebrae respectively were obtained from a
previous study of the same animals. The following parameters were
used in the current paper to aid interpretation of the results: activation
frequency (Ac.F), bone formation rate/bone surface (BFR/BS), osteoid
surface/bone surface (OS/BS), crack number (Cr.N), crack length
(Cr.Le), crack density (Cr.Dn), and crack surface density (Cr.S.Dn)
[25].
Statistical analysis
The statistical analyses included two-way analyses of variance for
repeated measures for the experimental apparent modulus, apparent
modulus predicted by the FE models, and matrix modulus. The group
(normal, risedronate, or alendronate) was used as the between-subjects
factor and testing direction (cranial–caudal, anterior–posterior,
medial–lateral) as the within-subjects factor. Bone volume fraction,
matrix density, histomorphometric parameters, and microdamage
parameters were analyzed using standard analysis of variance. When
signiﬁcant main eﬀects were found, speciﬁc comparisons were made
with Dunnett two-sided t-tests. In all cases, the exact p-values are
given; we considered p < 0:05 to represent signiﬁcant eﬀects.
A stepwise multiple regression analysis was used to assess the
suitability of the FE models for the prediction of the apparent modulus
measured in three directions in the laboratory. In this model the de-
pendent variable was the measured apparent modulus and the inde-
pendent variables were apparent modulus predicted by FE, testing
direction, and the treatment group. Correlation analysis was used to
examine the relations between the matrix density, matrix modulus, and
both remodelling and microdamage parameters. Statistical analyses
were performed using SPSS version 8.0 (SPSS Inc., Chicago, IL, USA).
Results
One dog was excluded due to distemper at the start
of treatment, and one vertebra was destroyed during
preparation. This left 11 control, 11 risedronate-treated,
and 12 alendronate-treated dogs. Bisphosphonate treat-
ment resulted in an increase in the bone volume frac-
tion and calciﬁed matrix density as determined using
Archimedes’ principle. The increase of approximately
2% in matrix density was signiﬁcant for both treat-
ments, but the change in BV/TV was only signiﬁcant for
the risedronate group where the increase was 18%
(Table 1).
The experimentally measured apparent modulus
was aﬀected by bisphosphonate treatment (p ¼ 0:001).
A signiﬁcant eﬀect of direction (p < 0:001) and an
Fig. 1. Deﬁnitions of the apparent level and the matrix level. The
matrix modulus was deﬁned as the modulus eﬀective at the scale of tens
to hundreds of microns. The apparent modulus was eﬀective at the
scale of millimeters to centimeters and includes both the inﬂuence of
the matrix modulus and the inﬂuence of trabecular architecture.
Table 1
Results for one-way ANOVA
Control Risedronate Alendronate ANOVA Control vs.
Risedronate
Control vs.
Alendronate
BV/TV 0.22 [0.20, 0.24] 0.26 [0.23, 0.28] 0.23 [0.22, 0.24] 0.009 0.007 0.657
qmatrix (g/cc) 2.09 [2.08, 2.11] 2.14 [2.11, 2.16] 2.13 [2.12, 2.14] 0.005 0.005 0.013
rultimate ðMPaÞ 8.3 [6.9, 9.6] 11.4 [10.4, 12.3] 9.8 [8.6, 10.9] 0.008 0.004 0.120
ryield ðMPaÞ 7.4 [6.1, 8.7] 10.2 [9.4, 11.0] 8.9 [8.0, 9.8] 0.004 0.002 0.070
Ac.F (year1) 1.65 [0.33, 4.18] 0.18 [0.03, 0.60] 0.09 [0.024, 0.16] 0.000 0.000 0.000
BFR/BS (lm3/lm2/year) 80.0 [18.6, 152.2] 10.5 [1.1, 36.9] 5.5 [1.4, 11.7] 0.000 0.000 0.000
OS/BS (%) 8.5 [5.8, 11.2] 1.5 [0.7, 2.2] 1.0 [0.6, 1.3] 0.000 0.000 0.000
Cr.N (#) 0.7 [0.3, 1.2] 3.3 [1.5, 5.0] 3.7 [2.8, 4.5] 0.001 0.003 0.001
Cr.Le (lm) 39.2 [22.3, 56.2] 49.4 [31.4, 67.4] 45.7 [40.6, 50.9] 0.557 – –
Cr.Dn (#/mm2) 0.33 [0.11, 0.54] 0.80 [0.41, 1.19] 1.19 [0.88, 1.51] 0.001 0.052 0.000
Cr.S.Dn (lm/mm2) 11.6 [3.8, 19.5] 39.8 [19.5, 60.0] 53.1 [39.8, 66.3] 0.000 0.011 0.000
Mean values and 95% conﬁdence intervals are presented on the left for histomorphometry (top), mechanical properties (middle), matrix density
(middle: qmatrix), and microdamage (bottom). On the right p-values are presented for both the ANOVA and the posthoc tests.
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interaction between direction and treatment (p ¼ 0:018)
were found. On average, the risedronate treated group
was 37% stiﬀer than the control group (p ¼ 0:001). No
signiﬁcant diﬀerence was found in the alendronate group
(p ¼ 0:215; Fig. 2A). The apparent modulus predicted
by the FE models (contribution of trabecular architec-
ture and bone mass) was also aﬀected by bisphospho-
nate treatment (p ¼ 0:001) with eﬀects similar to the
mechanical tests (Fig. 2B). As in the mechanical testing,
there was a signiﬁcant eﬀect of direction (p < 0:001), but
no interaction between direction and treatment (p ¼
0:246). The predicted apparent modulus in the risedro-
nate group was approximately 40% higher than the
control group (p < 0:001).Nosigniﬁcant eﬀectofalendro-
nate treatment was found (p ¼ 0:283; Fig. 2B). The
matrix modulus was not signiﬁcantly aﬀected by treat-
ment (p ¼ 0:517), nor was there signiﬁcant interaction
between direction and treatment group (p ¼ 0:893).
Direction signiﬁcantly aﬀected the matrix modulus,
which was 20–30% larger in the CC than in the AP
or ML directions (p < 0:001; Fig. 2C). Bisphosphonate
treatment resulted in an increase in both the ultimate
stress and the yield stress. However, after correcting
for architecture, this diﬀerence was not signiﬁcant
(Table 1).
In the multiple regression analysis, the FE models
(i.e., eﬀect of architecture and bone mass) accounted for
89.3% (p < 0:0001) of the variance in the experimentally
measured modulus. A small architecture independent
eﬀect of direction was found, which contributed to 0.5%
of the variance (p ¼ 0:04). Treatment group and direc-
tion-group interaction were not signiﬁcant. The residual
variance was 10.2%.
To estimate the statistical power of our results, we
simulated the predicted eﬀect of increased mineraliza-
tion on the matrix modulus. We assumed an increase of
5% in the mineralization of the bisphosphonate treated
group. For bone with a mineral fraction of approxi-
mately 40%, this agreed well with our observed matrix
density measurements. Based on the simulations we
predicted that the matrix modulus should increase by
between 5% (conservative linear model) and 14% (cubic
model) in the treated animals. From these simulations
we could estimate that, for the sample size used, the
power (b) to detect a diﬀerence in the group mean ma-
trix modulus with a two-sided t-test (a ¼ 0:05) was be-
tween 0.12 (for the conservative linear model) and 0.65
(for the cubic model). Because of the limited power of
our results, care must be taken when comparing the
group means for matrix modulus.
Because one sample from the control group was de-
stroyed during preparation, we reworked our previous
data [25], which are included in Table 1. From these data
a large signiﬁcant decrease in bone remodelling activity
is apparent in the bisphosphonate treated groups, as
well as an increased microdamage burden in the treated
animals as indicated by signiﬁcant increases in Cr.N,
Cr.Dn and Cr.S.Dn.
Apparent Modulus - Physical Testing
0
200
400
600
800
1000
1200
1400
CC AP ML
Axis
M
od
ul
us
 (M
P
a)
control
risedronate
alendronate
Apparent Modulus - FE Model
0
20
40
60
80
100
120
140
160
180
CC AP ML
Axis
M
od
ul
us
 (M
P
a)
control
risedronate
alendronate
Calcified Matrix Modulus
0
1
2
3
4
5
6
7
8
9
CC AP ML
Axis
M
od
ul
us
 (G
Pa
)
control
risedronate
alendronate
(A)
(B)
(C)
Fig. 2. Mechanical testing and FE simulation results. Cubes of tra-
becular bone from the ﬁrst lumbar vertebra were tested in three di-
rections in compression (Fig. 2A). FE models with a matrix modulus
of 1 GPa were used to quantify the contribution of trabecular archi-
tecture (Fig. 2B). The mineralized matrix modulus was the scaling
factor between the physical tests and the FE simulated results (Fig.
2C). Testing directions were cranial–caudal (CC), anteroposterior (AP)
and medial–lateral (ML). Results (mean+SEM) are grouped by test
direction on the x-axis of each graph. Treatment group is indicated by
the shading of the bars. (A): Apparent Young’s modulus from physical
testing. Two-way ANOVA indicated an eﬀect of treatment (p ¼ 0:015)
and direction (p < 0:001). Risedronate treated samples were signiﬁ-
cantly stiﬀer than the control group (p ¼ 0:012). (B): Relative modulus
calculated using FE models. Two-way ANOVA indicated an eﬀect of
treatment (p ¼ 0:001) and direction (p < 0:001). The simulated ap-
parent modulus of risedronate treated samples was signiﬁcantly stiﬀer
than the control group (p ¼< 0:001Þ. (C): Matrix modulus.
Bisphosphonate treatment had no eﬀect on the matrix modulus
(p ¼ 0:699). There was an eﬀect of direction (p < 0:001).
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Linear regression analysis revealed that the matrix
density was signiﬁcantly correlated to both the remod-
elling (ES/BS r ¼ 0:555, p ¼ 0:001; OS/BS r ¼ 0:594,
p < 0:001; BFR/BV r ¼ 0:487, p ¼ 0:004; Ac.F r ¼
0:353, p ¼ 0:044) and microdamage parameters (Cr.N
r ¼ 0:456, p ¼ 0:007; Cr.Dn r ¼ 0:412, p ¼ 0:015;
Cr.S.Dn r ¼ 0:511, p ¼ 0:002). The matrix modulus,
however, was not signiﬁcantly correlated to the matrix
density, remodelling, or microdamage parameters.
Discussion
The major purpose of this study was to determine
whether the increased levels of matrix mineralization
seen after long-term bisphosphonate therapy aﬀected the
matrix mechanical properties. We used a high dose to
simulate long-term eﬀects in the bone. Bone remodelling
was greatly reduced, resulting in both a 2% increase in
the matrix density (indicative of increased mineraliza-
tion) and increased microdamage accumulation. By
using a combination of FE modelling, microCT scan-
ning, and mechanical testing, we investigated the eﬀects
of treatment on the apparent Young’s modulus, bone
architecture, and calciﬁed matrix properties. A signiﬁ-
cant increase of the apparent modulus was observed in
the risedronate treated group. This increase was pre-
dicted by the FE models, indicating a strong eﬀect of
trabecular architecture and bone mass. The importance
of architecture was further indicated by the results of the
multiple regression analysis where 89.3% of the variance
in the mechanical testing was accounted for by the FE
models with no independent eﬀect of treatment group
(an eﬀect of treatment group would indicate a group
speciﬁc diﬀerence independent of the FE results, i.e.,
matrix modulus). Although the matrix density was in-
creased, there were no signiﬁcant diﬀerences in the
group mean matrix moduli.
A limitation of our study design is that we used in-
tact, normal’ dogs. In an osteoporotic population bone
turnover is likely increased, resulting in lower mean
mineralization of the calciﬁed matrix. Hypomineraliza-
tion in an osteoporotic population could lead to a de-
crease of the matrix modulus compared to the normal’
population used in this study.
Using microCT scans to create trabecular level FE
models requires that the scan be of suﬃcient resolution
and quality to resolve individual trabeculae accurately.
Our use of 36 lm voxels and individual thresholds was
suﬃcient to create accurate meshes [30]. We found an
average matrix modulus of 5.9 GPa, well within the
range previously reported using this method [9,18,38,41].
Initially, we were concerned that the reduction in the
amount of osteoid in the bisphosphonate treated groups
could bias our segmentation of the CT data. Calculations
indicated that the quantity of unmineralized osteoid
tissue was not large enough to inﬂuence the choice of
thresholds (data not shown). Further, we found no sig-
niﬁcant relation between OS/BS and matrix modulus
(0:416 p6 0:72 for Pearson correlation depending on
direction) and concluded that this factor had little or no
eﬀect on the model results.
We found that the matrix modulus was inﬂuenced by
the testing direction (Fig. 2C). This could be due to
preferential loss of material due to thresholding in the
presence of strong anisotropy at the trabecular level [20],
non-ideal behavior (i.e. buckling of trabeculae) that is
not represented in the FE model’s boundary conditions
[17,19], non-ideal behavior of the model’s linear brick-
shaped elements [21], or true material anisotropy at the
sub-trabecular level [32].
Clinically a large increase in BMD has been observed
in the ﬁrst year of antiresorptive therapy. Following
this, BMD either slowly increases or reaches a plateau
[26,37]. It was believed that the initial gain in BMD was
indicative of an increase in bone mass due to the tran-
sient change in remodelling space and that the later gain
in BMD was the result of increased mineralization. It
has recently been suggested that increased secondary
mineralization, rather than bone mass, is responsible for
the reduced fracture risk after alendronate therapy [3].
In a two-year clinical study of alendronate therapy, the
authors observed an increase in spinal BMD, but no
signiﬁcant increase in bone mass in transiliac biopsies.
Analysis of the biopsies by contact microradiography
revealed 9.3% and 7.3% increases in the mean degree of
mineralization of cortical and trabecular bone, respec-
tively. Based on these ﬁndings, the authors concluded
that the reduction of fracture incidence was due to sec-
ondary mineralization rather than increased bone mass.
This contradicts a previous study of ovariectomized
primates where an increase in the bone volume fraction
was measured after two years of treatment with
alendronate as compared to saline vehicle treated ani-
mals [1]. The extrapolation of results obtained from iliac
biopsies to spine BMD as measured by DEXA is tenu-
ous as this study was underpowered to detect diﬀerences
in the iliac crest. Also, large diﬀerences in remodelling
can exist between the spine and iliac crest [13].
While it is logical that normalizing the mineralization
of hypomineralized bone in osteoporotics to normal
levels should be beneﬁcial to the patient, the exclusion
of the contribution of increased bone mass is not sup-
ported by our data. Although we predicted an increase
of at least 5% for the matrix modulus based on our
measurements of increased matrix density, we observed
only small insigniﬁcant changes in the moduli of the
calciﬁed matrix in the bisphosphonate treated groups
(5% decrease in risedronate treated group and a 1% in-
crease in the alendronate treated group; Fig. 2C).
Based on our data, we conclude that the increased
apparent modulus seen in bisphosphonate therapy
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results from increased bone mass and altered trabecular
architecture. This is supported by a concurrent study of
the three-dimensional morphology of specimens from
the same animals [11]. Our results are in agreement with
the clinical data, where the greatest reduction in fracture
risk occurs during the ﬁrst year of treatment, but fewer
fractures are also found in subsequent years compared
to placebo treated controls [2,10,14]. It would seem
likely that reduction of fracture risk seen clinically in
bisphosphonate therapy is the result of the increase in
bone mass early in the treatment as the remodelling
space is ﬁlled in’. Further increase in BMD through
secondary mineralization could provide some beneﬁt in
the short term at clinical doses but may be harmful to
the patient in the long term as microdamage accumlates.
In the present study there was a signiﬁcant positive
correlation between tissue density and microdamage
accumulation. We speculate that increased matrix me-
chanical properties due to mineralization may have been
obscured by increased microdamage. Therefore, clinical
dosing regimens should be chosen carefully to ensure
adequate bone turnover.
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